Article
Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Maximizing the 2-Fold Benefits of Your Charitable Donations
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Baricitinib Shows Superior Efficacy Versus Traditional Alopecia Treatments
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Heart Transplant Recipients are More Susceptible to Skin Cancer
Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881